Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.61 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | HTR5A | P47898 | 1/20 | 0.47 |
| ▸ | TDP2 | O95551 | 4/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | CASP9 | P55211 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.46 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.43 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15621406 | 0.84 | TDP2 (0.56) | AHRPDK2HTR5ATDP2CASP3 | |
| SCHEMBL5007554 | 0.83 | AHR (0.45) | AHRPDK2HTR5ATDP2CASP3 | |
| SCHEMBL2675583 | 0.82 | SRD5A1 (0.57) | AHRHTR5ASRD5A1CA12CA1 | |
| SCHEMBL5497492 | 0.81 | AHR (0.44) | AHRPDK2HTR5ATDP2CASP3 | |
| Hydrochloric Acid SCHEMBL30293224 | 0.81 | SRD5A1 (0.55) | AHRHTR5ASRD5A1CA12CA1 | |
| SCHEMBL10955919 | 0.80 | SMYD3 (0.52) | AHRPDK2TDP2CASP3CASP7 | |
| SCHEMBL22469447 | 0.79 | MAPT (0.53) | AHRHTR5ASRD5A1OPRL1CA12 | |
| SCHEMBL15966849 | 0.79 | AHR (0.41) | AHRPDK2HTR5ATDP2CASP3 | |
| SCHEMBL8765618 | 0.77 | SRD5A1 (0.41) | AHRHTR5ATDP2CASP3CASP7 | |
| SCHEMBL22904178 | 0.77 | TDP2 (0.64) | AHRPDK2TDP2CASP3CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | claimed |
| EP-3901153-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2021-10-27 | — | — | EP | claimed |
| US-20210284641-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-16 | — | — | US | claimed |
| EP-3288940-B9 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-21 | — | — | EP | claimed |
| EP-3288940-B1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-24 | — | — | EP | claimed |
| US-20180118740-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | claimed |
| EP-3288940-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-03-07 | — | — | EP | claimed |
| WO-2016176460-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | WO | claimed |
| US-7754895-B2 | Process for the synthesis of progesterone receptor modulators | WYETH LLC (US) | 2010-07-13 | — | — | US | claimed |
| WO-2007016355-A2 | PROCESS FOR THE SYNTHESIS OF PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2007-02-08 | — | — | WO | claimed |
| US-20070027327-A1 | Process for the synthesis of progesterone receptor modulators | WYETH (US) | 2007-02-01 | — | — | US | claimed |
| CN-116546990-B | CD73 inhibitor and pharmaceutical application thereof | RISEN (SUZHOU) PHARMA TECH Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| EP-4736854-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4514473-B1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4676590-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | Zoetis Services LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-0208510-B1 | 1-SUBSTITUTED OXINDOLE-3-CARBOXAMINES AS ANTIINFLAMMATORY AND ANALGESIC AGENTS | PFIZER INC. (US) | 1991-09-11 | — | — | EP | disclosed |
| US-4791129-A | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS | PFIZER INC. (US) | 1988-12-13 | — | — | US | disclosed |
| US-4725616-A | ANTIARTHRITIC AGENTS | PFIZER INC. (US) | 1988-02-16 | — | — | US | disclosed |
| EP-0208510-A2 | 1-Substituted oxindole-3-carboxamines as antiinflammatory and analgesic agents | PFIZER INC. (US) | 1987-01-14 | — | — | EP | disclosed |
| US-4160032-A | Oxindoles as sleep-inducers | SANDOZ, INC. (US) | 1979-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284641-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | AHR 2068/4885PDK2 1993/4885HTR5A 555/4885 |
| US-20180118740-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | AHR 2068/4885PDK2 1993/4885HTR5A 555/4885 |
| US-20070027327-A1 | Process for the synthesis of progesterone receptor modulators | PGR, OXTR, PGRMC1 | AHR 439/4885PDK2 405/4885HTR5A 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.